Australia Markets closed

Xenon Pharmaceuticals Inc. (XENE)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
27.49+0.95 (+3.58%)
At close: 04:00PM EDT
27.49 0.00 (0.00%)
After hours: 04:00PM EDT
Currency in USD

Valuation measures4

Market cap (intra-day) N/A
Enterprise value N/A
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)N/A
Price/book (mrq)N/A
Enterprise value/revenue N/A
Enterprise value/EBITDA N/A

Trading information

Stock price history

Beta (5Y monthly) 1.79
52-week change 3N/A
S&P500 52-week change 3N/A
52-week high 336.42
52-week low 314.65
50-day moving average 330.50
200-day moving average 327.82

Share statistics

Avg vol (3-month) 3466.12k
Avg vol (10-day) 3482.71k
Shares outstanding 551.59M
Implied shares outstanding 6N/A
Float 839.91M
% held by insiders 12.16%
% held by institutions 193.50%
Shares short (28 Apr 2022) 42.01M
Short ratio (28 Apr 2022) 44.85
Short % of float (28 Apr 2022) 43.84%
Short % of shares outstanding (28 Apr 2022) 43.79%
Shares short (prior month 30 Mar 2022) 42.17M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 3N/A
Trailing annual dividend yield 3N/A
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 30 Dec 2021
Most-recent quarter (mrq)30 Dec 2021


Profit margin 0.00%
Operating margin (ttm)-428.45%

Management effectiveness

Return on assets (ttm)-12.97%
Return on equity (ttm)-21.87%

Income statement

Revenue (ttm)18.44M
Revenue per share (ttm)0.35
Quarterly revenue growth (yoy)-27.40%
Gross profit (ttm)-57.03M
EBITDA -78.09M
Net income avi to common (ttm)-78.88M
Diluted EPS (ttm)-1.55
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)551.77M
Total cash per share (mrq)10.42
Total debt (mrq)8.26M
Total debt/equity (mrq)1.50
Current ratio (mrq)39.03
Book value per share (mrq)5.87

Cash flow statement

Operating cash flow (ttm)-69.5M
Levered free cash flow (ttm)-43.76M